{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:25:53Z","timestamp":1787725553364,"version":"build-2784847793"},"reference-count":54,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp;amp; Rheumatology"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular\u2010course juvenile idiopathic arthritis (pcJIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open\u2010label study, enrolled patients aged 2 to 17 years with active pcJIA and inadequate response or intolerance to at least one disease\u2010modifying antirheumatic drug. Original CZP doses, based on pharmacokinetic model simulations, included loading and then 50, 100, or 200 mg maintenance doses once every two weeks for patients 10 to &lt;20, 20 to &lt;40, or \u226540 kg, respectively. After interim analyses, loading or maintenance doses reduced by 50% for some patients. Prespecified primary outcomes were plasma CZP concentrations, treatment\u2010emergent adverse events (TEAEs), and anti\u2010CZP antibodies (ADAb) at week (Wk)16 and Wk48. Secondary effectiveness outcomes are reported through nine years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 193 patients were enrolled and observed for a median of 3.45 (minimum 0.04, maximum 11.39) years. At Wk16, 151 of 193 patients (78.2%) achieved JIA American College of Rheumatology Pediatric 50 criteria at any CZP dosage, and the median 71\u2010joint Juvenile Arthritis Disease Activity Score decreased from 23.5 at baseline to 4.0 at Wk16. Mean plasma CZP concentrations reached steady state at Wk12 and were lower with reduced dose than original dose (reduced dose: mean 8.4 [95% confidence interval 6.2\u201311.4] \u03bcg\/mL; original dose: mean 33.4 [95% confidence interval 27.4\u201340.7] \u03bcg\/mL). Serious TEAEs occurred in 46 of 193 patients (23.8%). Chronic ADAb positivity was common (&gt;79.0% by Wk12) and associated with lower CZP concentrations, but it maintained response to CZP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Open\u2010label CZP treatment demonstrated rapid, long\u2010term clinical improvements, an acceptable safety profile, and tolerability in patients with pcJIA. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70274","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:27:47Z","timestamp":1783942067000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+\u2010Year Results From a Multicenter, Open\u2010Label Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Grebenkina","sequence":"additional","affiliation":[{"name":"Togliatti City Clinical Hospital N\u00b05  Togliatti Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Nikishina","sequence":"additional","affiliation":[{"name":"V.A. Nasonova Research Institute of Rheumatology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Alexeeva","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Children's Health  Moscow Russia"},{"name":"Sechenov First Moscow State Medical University  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Chasnyk","sequence":"additional","affiliation":[{"name":"St Petersburg State Pediatric Medical University  St Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5831","authenticated-orcid":false,"given":"Carlos","family":"Abud\u2010Mendoza","sequence":"additional","affiliation":[{"name":"Hospital Central &amp; Facultad de Medicina Universidad Aut\u00f3noma de San Luis Potos\u00ed  San Luis Potos\u00ed Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadina","family":"Rubio\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Nuevo Le\u00f3n Hospital Universitario \u201cDr. Jos\u00e9 E. Gonz\u00e1lez\u201d Department of Pediatrics  Monterrey Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-8946","authenticated-orcid":false,"given":"Heinrike","family":"Schmeling","sequence":"additional","affiliation":[{"name":"Alberta Children's Hospital, Section of Rheumatology, Department of Pediatrics Cumming School of Medicine, University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Rocio Maldonado\u2010Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"Hospital Infantil de Mexico Federico Gomez  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Brown","sequence":"additional","affiliation":[{"name":"Children's Hospital of Los Angeles  Los Angeles California"},{"name":"University of Southern California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zeft","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Pediatric Rheumatology  Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-1781","authenticated-orcid":false,"given":"Esi","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Seattle Children's Hospital, Department of Pediatrics University of Washington School of Medicine  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Egla","family":"Rabinovich","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology Duke University Medical Center  Durham North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kingsbury","sequence":"additional","affiliation":[{"name":"Randall Children's Hospital at Legacy Emanuel  Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya","family":"Bukulmez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, MetroHealth Medical System Case Western Reserve University  Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Northwell Health, Cohen Children's Medical Center, Pediatric Rheumatology  New Hyde Park New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Griffin","sequence":"additional","affiliation":[{"name":"Levine Children's Hospital  Charlotte North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Imundo","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center  New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-7878","authenticated-orcid":false,"given":"Stacey","family":"Tarvin","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children  Indianapolis Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl","family":"Silverman","sequence":"additional","affiliation":[{"name":"Hospital for Sick Children  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"UCB Pharma  Morrisville North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Shimizu","sequence":"additional","affiliation":[{"name":"UCB  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Williams","sequence":"additional","affiliation":[{"name":"UCB Pharma  Morrisville North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Lled\u00f3\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"UCB  Slough United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Utturkar","sequence":"additional","affiliation":[{"name":"UCB  Slough United Kingdom"},{"name":"UCB, Malvern  Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baran","family":"Ufuktepe","sequence":"additional","affiliation":[{"name":"UCB  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi di Genova  Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-0130","authenticated-orcid":false,"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine  Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia Universit\u00e0 degli Studi di Milano\u2010Bicocca  Milano Italy"},{"name":"SC Reumatologia Pediatrica Fondazione IRCCS San Gerardo dei Tintori  Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Paediatric Rheumatology International Trials Organisation (PRINTO); the Pediatric Rheumatology Collaborative Study Group (PRCSG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00332-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00443-8"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41390"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_8_6_1","unstructured":"US Food and Drug Administration.CIMZIA (certolizumab pegol). Accessed March 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125160s275lbl.pdf."},{"key":"e_1_2_8_7_1","unstructured":"European Medicines Agency.Cimzia: certolizumab pegol. Accessed March 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cimzia\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_8_8_1","unstructured":"Pediatric arthritis study of certolizumab pegol (PASCAL). ClinicalTrials.gov\u2009identifier: NCT01550003. Updated October 23 2024. Accessed March 2025.https:\/\/clinicaltrials.gov\/study\/NCT01550003."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.188946"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27670"},{"key":"e_1_2_8_11_1","volume-title":"Guideline for Good Clinical Practice E6(R1)","author":"International Council for Harmonisation","year":"1996"},{"issue":"10","key":"e_1_2_8_12_1","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"Petty RE","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_8_13_1","unstructured":"A study of the safety and effectiveness of lyophilized certolizumab pegol in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis (RAPID 2). ClinicalTrials.gov\u2009identifier: NCT00175877. Updated March 26 2020. Accessed March 2025.https:\/\/clinicaltrials.gov\/study\/NCT00175877."},{"key":"e_1_2_8_14_1","unstructured":"A placebo controlled study to assess efficacy and safety of certolizumab pegol in the treatment of rheumatoid arthritis. ClinicalTrials.gov\u2009identifier: NCT00152386. Updated December 1 2020. Accessed June 2025.https:\/\/clinicaltrials.gov\/study\/NCT00152386."},{"key":"e_1_2_8_15_1","unstructured":"A study of liquid certolizumab pegol as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis. ClinicalTrials.gov\u2009identifier: NCT00160602. Updated December 1 2020. Accessed June 2025.https:\/\/clinicaltrials.gov\/study\/NCT00160602."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13220"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001208"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290216"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"issue":"4","key":"e_1_2_8_23_1","first-page":"S1","article-title":"Paediatric Rheumatology International Trials Organisation. Cross\u2010cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology","volume":"19","author":"Ruperto N","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213150"},{"issue":"11","key":"e_1_2_8_26_1","first-page":"2290","article-title":"Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace CA","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00672-5"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60413-8"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-18"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.02.753"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204948"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1768:AID-ART312>3.0.CO;2-Q"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02326-5"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38741"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038002"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00798-8"},{"key":"e_1_2_8_37_1","unstructured":"A study to test the efficacy and safety of certolizumab pegol in Japanese subjects with moderate to severe chronic psoriasis. ClinicalTrials.gov\u2009identifier: NCT03051217. Updated January 4 2022. Accessed June 2025.https:\/\/clinicaltrials.gov\/study\/NCT03051217."},{"key":"e_1_2_8_38_1","unstructured":"Study to evaluate maintenance of sustained remission of axSpA with CZP compared to placebo (C\u2010OPTIMISE). ClinicalTrials.gov\u2009identifier: NCT02505542. Updated December 17 2020. Accessed June 2025.https:\/\/clinicaltrials.gov\/study\/NCT02505542."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/nlr4r8"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203695"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31651-8"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0841-9"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203843"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030387"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/bacteria3030014"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23964"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34343"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064717"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20044"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23709"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073445"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:44:12Z","timestamp":1787723052000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":54,"alternative-id":["10.1002\/art.70274"],"URL":"https:\/\/doi.org\/10.1002\/art.70274","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"2026-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"art.70274"}}